CYTK
$62.13
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Intraday
Recent News
Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes
Why new MYQORZO data is back in focus for Cytokinetics (CYTK) Cytokinetics (CYTK) is back on investors’ radar after fresh MYQORZO data at the American College of Cardiology meeting highlighted exercise capacity benefits, a consistent safety profile, and flexibility around temporary treatment interruptions. See our latest analysis for Cytokinetics. At a share price of US$60.83, Cytokinetics has seen a 1-day share price return of 1.28% and a 30-day share price return decline of 8.20%. However,...
Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab
Cytokinetics (NASDAQ:CYTK) executives told investors at the Barclays healthcare conference that the company’s U.S. launch of MYQORZO is still in its earliest phase but showing what management described as encouraging initial signs, while a key phase 3 readout in non-obstructive hypertrophic cardiomy
Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference
Cytokinetics (NASDAQ:CYTK) used its presentation at the Leerink Global Healthcare Conference to outline its transition from a long-running research-focused company into a commercial-stage cardiovascular drug developer following the recent approval of aficamten, marketed as MYQORZO, for obstructive h
Cytokinetics Teases Q2 Phase 3 ACACIA-HCM Readout as Myqorzo Launch Gains Traction at Citi Conference
Cytokinetics (NASDAQ:CYTK) used its presentation at Citi’s Life Sciences Conference to highlight the recent U.S. approval of its first drug, Myqorzo, and to preview an upcoming Phase 3 readout in non-obstructive hypertrophic cardiomyopathy (NHCM) that management described as a major near-term cataly
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
This biopharma company advancing cardiac drug candidates disclosed a notable insider sale amid late-stage clinical development.